• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

    Thumbnail
    View/ Open
    1756-8722-6-17.pdf (674.1Kb)

    Show full item record
    
    Author
    Wun, Ted; Soulieres, Denis; Frelinger, Andrew L; Krishnamurti, Lakshmanan; Novelli, Enrico M; Kutlar, Abdullah; Ataga, Kenneth I; Knupp, Charles L; McMahon, Lillian E; Strouse, John J; Zhou, Chunmei; Heath, Lori E; Nwachuku, Chuke E; Jakubowski, Joseph A; Riesmeyer, Jeffrey S; Winters, Kenneth J
    Abstract
    Background Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SCD, we conducted a double-blind, randomized, placebo-controlled study. Methods The primary endpoint, safety, was measured by hemorrhagic events requiring medical intervention. Patients were randomized to prasugrel 5 mg daily (n = 41) or placebo (n = 21) for 30 days. Platelet function by VerifyNow® P2Y12 and vasodilator-stimulated phosphoprotein assays at days 10 and 30 were significantly inhibited in prasugrel- compared with placebo-treated SCD patients. Results There were no hemorrhagic events requiring medical intervention in either study arm. Mean pain rate (percentage of days with pain) and intensity in the prasugrel arm were decreased compared with placebo. However, these decreases did not reach statistical significance. Platelet surface P-selectin and plasma soluble P-selectin, biomarkers of in vivo platelet activation, were significantly reduced in SCD patients receiving prasugrel compared with placebo. In sum, prasugrel was well tolerated and not associated with serious hemorrhagic events. Conclusions Despite the small size and short duration of this study, there was a decrease in platelet activation biomarkers and a trend toward decreased pain.
    URI
    http://hdl.handle.net/10342/8278
    Subject
    Prasugrel, Sickle cell disease, Thienopyridine, Platelet function
    Date
    2013-02
    Citation:
    APA:
    Wun, Ted, & Soulieres, Denis, & Frelinger, Andrew L, & Krishnamurti, Lakshmanan, & Novelli, Enrico M, & Kutlar, Abdullah, & Ataga, Kenneth I, & Knupp, Charles L, & McMahon, Lillian E, & Strouse, John J, & Zhou, Chunmei, & Heath, Lori E, & Nwachuku, Chuke E, & Jakubowski, Joseph A, & Riesmeyer, Jeffrey S, & Winters, Kenneth J. (February 2013). A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. Journal of Hematology and Oncology, (6:17), p.1-10. Retrieved from http://hdl.handle.net/10342/8278

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Wun, Ted, and Soulieres, Denis, and Frelinger, Andrew L, and Krishnamurti, Lakshmanan, and Novelli, Enrico M, and Kutlar, Abdullah, and Ataga, Kenneth I, and Knupp, Charles L, and McMahon, Lillian E, and Strouse, John J, and Zhou, Chunmei, and Heath, Lori E, and Nwachuku, Chuke E, and Jakubowski, Joseph A, and Riesmeyer, Jeffrey S, and Winters, Kenneth J. "A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease". Journal of Hematology and Oncology. 6:17. (1-10.), February 2013. March 08, 2021. http://hdl.handle.net/10342/8278.
    Chicago:
    Wun, Ted and Soulieres, Denis and Frelinger, Andrew L and Krishnamurti, Lakshmanan and Novelli, Enrico M and Kutlar, Abdullah and Ataga, Kenneth I and Knupp, Charles L and McMahon, Lillian E and Strouse, John J and Zhou, Chunmei and Heath, Lori E and Nwachuku, Chuke E and Jakubowski, Joseph A and Riesmeyer, Jeffrey S and Winters, Kenneth J, "A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease," Journal of Hematology and Oncology 6, no. 17 (February 2013), http://hdl.handle.net/10342/8278 (accessed March 08, 2021).
    AMA:
    Wun, Ted, Soulieres, Denis, Frelinger, Andrew L, Krishnamurti, Lakshmanan, Novelli, Enrico M, Kutlar, Abdullah, Ataga, Kenneth I, Knupp, Charles L, McMahon, Lillian E, Strouse, John J, Zhou, Chunmei, Heath, Lori E, Nwachuku, Chuke E, Jakubowski, Joseph A, Riesmeyer, Jeffrey S, Winters, Kenneth J. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. Journal of Hematology and Oncology. February 2013; 6(17) 1-10. http://hdl.handle.net/10342/8278. Accessed March 08, 2021.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback